Using combination therapy to overcome insufficient responses in programmed death ligand-1 (PD-1) inhibitors
Mechanism of action of PD-1 and PD-L1 inhibitors. Tumor cells develop... | Download Scientific Diagram
Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection - ScienceDirect
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway | NEJM
Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms - Annals of Oncology
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker - Wang - 2020 - Cancer Medicine - Wiley Online Library
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation | Journal of Medicinal Chemistry
Frontiers | PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy - ScienceDirect
Immune checkpoint blockade in HIV - eBioMedicine
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Opdualag Approved to Treat Advanced Melanoma - NCI
In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors
In Vitro Potency Assays for Assessing the Function of anti-PD-1 Checkpoint Inhibitors
IMMUNTERAPI
Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer
Current Oncology | Free Full-Text | Immune Checkpoint Inhibitors in Cancer Therapy
Cancers | Free Full-Text | PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation | Journal of Medicinal Chemistry
PD-1 and PD-L1 inhibitors - Wikipedia
JCI - Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway | Acta Pharmacologica Sinica
Biomarkers of response to PD-1 pathway blockade | British Journal of Cancer
Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?
